NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 60 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 1.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | -100.0% | 265 | 0.0% | 0.00% | – |
| Q2 2023 | $1 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -100.0% | 265 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | 0.0% | 265 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | -25.0% | 265 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -20.0% | 265 | 0.0% | 0.00% | – |
| Q4 2021 | $5,000 | -16.7% | 265 | 0.0% | 0.00% | – |
| Q3 2021 | $6,000 | +100.0% | 265 | +81.5% | 0.00% | – |
| Q2 2021 | $3,000 | -25.0% | 146 | 0.0% | 0.00% | – |
| Q1 2021 | $4,000 | 0.0% | 146 | +12.3% | 0.00% | – |
| Q4 2020 | $4,000 | -33.3% | 130 | -65.4% | 0.00% | – |
| Q3 2020 | $6,000 | +20.0% | 376 | 0.0% | 0.00% | – |
| Q2 2020 | $5,000 | 0.0% | 376 | 0.0% | 0.00% | – |
| Q1 2020 | $5,000 | -28.6% | 376 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | – | 376 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |